Drug Trial Radar · NCT03279302
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Dec 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Sep 4, 2017
Primary completion
Dec 18, 2017
Study completion Dec 18, 2017
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 12, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the trial is to characterize the pharmacokinetic (PK) profiles of glepaglutide and its primary active metabolites following once-daily and once-weekly subcutaneous (SC) injections and after a single intravenous (IV) infusion in healthy subjects. Glepaglutide is a proposed International Nonproprietary Name for ZP1848
Conditions
- Healthy Subjects
Interventions
GlepaglutideDrug
Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic parameter - half lifeTime frame: Day 0 up to Day 73
- Pharmacokinetic parameter - total body clearanceTime frame: Day 0 to Day 22
- Pharmacokinetic parameter - Apparent clearanceTime frame: Day 0 to Day 73
- Pharmacokinetic parameter - Volume of distributionTime frame: Day 0- Day 22
- Pharmacokinetic parameter - apparent volume of distributionTime frame: Day 0 to Day 73
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance CRU
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.